Company plans to start selling bioequivalent version of AstraZeneca’s Atenol tablets in Q1 ’07.

Ranbaxy Laboratories (RLL) received approval for its generic version of AstraZeneca’s hypertension drug. “This will further expand our product portfolio of affordable generic alternatives to the brand in the treatment of cardiovascular disorders,” says Jim Meehan, vp of sales and marketing for Ranbaxy Pharmaceuticals, a wholly owned subsidiary of RLL.

Atenolol tablets USP, 25 mg, 50 mg, and 100 mg were deemed bioequivalent and have the same therapeutic effect as Tenormin®. Besides hypertension, Atenolol is also indicated for the long-term management of patients with angina pectoris due to coronary atherosclerosis and the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality.

The company reports that according to IMS data, total annual market sales for Atenolol were $133.6 million. RLL expects to start selling its generic during the first quarter of 2007.

Previous articlePerkinElmer Buys Thermal Analysis Product Line
Next articleHematech Produces Healthy Prion Protein-Knockout Cows